Skip to main content
Aptorum Group Ltd logo

Aptorum Group Ltd — Investor Relations & Filings

Ticker · APM ISIN · KYG6096M1069 US Manufacturing
Filings indexed 257 across all filing types
Latest filing 2026-03-27 Annual Report
Country US United States of America
Listing US APM

About Aptorum Group Ltd

https://www.aptorumgroup.com/

Aptorum Group Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics to address unmet medical needs. The company's research and development pipeline targets a range of therapeutic areas, including orphan oncology, infectious diseases, and metabolic diseases. Key projects include SACT-1, a repurposed drug candidate for neuroblastoma, and ALS-4, an anti-virulence, non-bactericidal therapeutic for infections caused by Staphylococcus aureus. Additionally, the company is developing its RPIDD (Rapid Pathogen Identification and Detection Diagnostics) platform, a liquid biopsy-based technology for rapidly identifying and detecting pathogens.

Recent filings

Filing Released Lang Actions
20-F - Aptorum Group Ltd (0001734005) (Filer)
Annual Report
2026-03-27 English
6-K Filing
Foreign Filer Report
2026-02-06 English
S-4/A Filing
Registration Form
2026-01-21 English
REGISTRATION STATEMENT
Regulatory Filings
2026-01-16 English
PROSPECTUS SUPPLEMENT
Prospectus
2025-12-05 English
AMENDMENT NO. 1 TO FORM 6-K
Foreign Filer Report
2025-12-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.